Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Tyra Biosciences, Inc. - Common Stock
(NQ:
TYRA
)
38.02
+0.10 (+0.26%)
Streaming Delayed Price
Updated: 1:51 PM EDT, Mar 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tyra Biosciences, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit
↗
Today 13:54 EDT
This Boston-based biotech develops therapies for neurological disorders, with a pipeline targeting depression, tremor, and rare epilepsies.
Via
The Motley Fool
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer
↗
February 23, 2026
Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs.
Via
The Motley Fool
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake
↗
February 23, 2026
Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments.
Via
The Motley Fool
Topics
Regulatory Compliance
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million
↗
February 23, 2026
Spyre Therapeutics develops preclinical monoclonal antibody therapies targeting inflammatory bowel disease and related conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50%
↗
February 23, 2026
Centessa Pharmaceuticals develops clinical-stage therapies for rare and serious diseases, leveraging a portfolio approach in biopharma.
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29%
↗
February 23, 2026
Nuvalent develops targeted cancer therapies, advancing clinical candidates for patients with limited treatment options in oncology.
Via
The Motley Fool
Topics
Regulatory Compliance
Tyra Biosciences Director Sells 247,000 Shares for $5 Million After 38% Rally
↗
December 23, 2025
Focused on precision oncology and rare genetic diseases, this biotech reported a significant insider sale amid strong one-year stock gains.
Via
The Motley Fool
Topics
Regulatory Compliance
Tyra Biosciences Narrows Loss in Q2
↗
August 14, 2025
Via
The Motley Fool
Which stocks are moving before the opening bell on Tuesday?
↗
April 22, 2025
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via
Chartmill
Northrop Grumman Posts Downbeat Results, Joins Halliburton And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
↗
April 22, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
April 22, 2025
Via
Benzinga
Why Calix Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
↗
April 22, 2025
Via
Benzinga
Why WaFd Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
↗
April 14, 2025
Via
Benzinga
Why Penguin Solutions Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
↗
April 03, 2025
Via
Benzinga
Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
↗
March 17, 2025
Via
Benzinga
Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
↗
March 17, 2025
Via
Benzinga
Neumora Therapeutics, XPeng And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
↗
January 02, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
October 29, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
↗
October 25, 2024
Via
Benzinga
Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday?
↗
October 25, 2024
Tyra Biosciences shares TYRA-300 Phase 1/2 data in metastatic urothelial cancer with 100% disease control at ≥90 mg doses and favorable safety.
Via
Benzinga
BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug
↗
October 18, 2024
Tyra Biosciences receives an upgrade from BofA, raising the price target to $31. The upgrade follows promising preclinical data for TYRA-300 and increased sales projections for metastatic urothelial...
Via
Benzinga
This Datadog Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
↗
October 18, 2024
Via
Benzinga
TYRA Investors Have Opportunity to Join Tyra Biosciences, Inc. Securities Fraud Investigation with the Schall Law Firm
August 20, 2024
From
The Schall Law Firm
Via
Business Wire
TYRA Stock Earnings: Tyra Biosciences Beats EPS for Q2 2024
↗
August 07, 2024
TYRA stock results show that Tyra Biosciences beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday
↗
July 12, 2024
Via
Benzinga
TYRA Stock Earnings: Tyra Biosciences Beats EPS for Q1 2024
↗
May 09, 2024
TYRA stock results show that Tyra Biosciences beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
TYRA Stock Earnings: Tyra Biosciences Misses EPS for Q4 2023
↗
March 19, 2024
TYRA stock results show that Tyra Biosciences missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
S&P 500 Gains Over 1%; Amazon Earnings Top Expectations
↗
February 02, 2024
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 1.8% on Friday. The Dow traded up 0.49% to 38,705.29 while the NASDAQ rose 1.81% to 15,639.81. The S&P 500...
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Friday's Intraday Session
↗
February 02, 2024
Via
Benzinga
Why Skechers Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
February 02, 2024
Shares of Skechers U.S.A., Inc. (NYSE: SKX) shares fell during Friday’s session after the company reported mixed fourth-quarter financial results.
Via
Benzinga
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
